Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood-donor screening.

@article{Tobler2003ImpactOH,
  title={Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood-donor screening.},
  author={Leslie H. Tobler and Susan L. Stramer and Stephen R. Lee and Barbara L. Masecar and Jon E. Peterson and Elizabeth Anne Davis and William Edward Andrews and Jaye P. Brodsky and Steven H. Kleinman and Bruce H. Phelps and Michael P. Busch},
  journal={Transfusion},
  year={2003},
  volume={43 10},
  pages={
          1452-9
        }
}
BACKGROUND In 1996, the Ortho HCV Version 3.0 ELISA Test System (HCV 3.0 EIA) was licensed in the United States for donor screening but was neither mandated nor universally implemented. Data from two studies comparing the differential performance of HCV 3.0 EIA and HCV 2.0 EIA are presented. The first study evaluated the differential performance in a cross-section of screened whole-blood donors after implementation of HCV 3.0 EIA; the second study evaluated the differential performance of HCV 3… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

Interleukins 12 and 13 levels among beta-thalassaemia major patients.

  • Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit
  • 2013
VIEW 2 EXCERPTS
HIGHLY INFLUENCED

Quantitative estimation of interferon-gamma levels among Egyptian polytransfused haematology cases.

  • Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit
  • 2013
VIEW 1 EXCERPT
CITES METHODS